SCHEMBL31696416

SCHEMBL31696416

NC(=O)c1ccnc(OC(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 5/20 0.42
▸ BCR P11274 4/20 0.42
▸ KDM4B O94953 1/20 0.41
▸ KDM5C P41229 1/20 0.41
▸ KDM5B Q9UGL1 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ SYK P43405 1/20 0.37
▸ CHEK2 O96017 1/20 0.37
▸ PARP1 P09874 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20916908 1.00 ABL1 (0.42) ABL1BCRKDM4BKDM5CKDM5B
SCHEMBL2304236 0.85 KDM4C (0.50) KDM4BKDM5CKDM5BKDM4EMAPT
SCHEMBL30281370 0.81 EPHX2 (0.52) KDM4BKDM5CKDM5BMAPTMAPK1
Trifluoroacetic Acid SCHEMBL16761281 0.78 NNMT (0.46) KDM4EMAPK1OPRK1KCNH2MKNK1
SCHEMBL445784 0.77 NNMT (0.56) KDM4BKDM5CKDM5BKDM4EMAPK1
SCHEMBL30281222 0.77 NNMT (0.56) KDM4BKDM5CKDM5BKDM4EMAPK1
SCHEMBL23062888 0.77 KDM4B (0.41) KDM4BKDM5CKDM5BKDM4EOPRK1
SCHEMBL31322442 0.77 KDM4B (0.41) KDM4BKDM5CKDM5BKDM4EOPRK1
SCHEMBL31481235 0.76 GABRP (0.41) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL1758489 0.76 SCN10A (0.62) ABL1BCRKDM4BKDM5CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 — — US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS KCNT1, KCNT2, KCNN3 ABL1 1561/4885BCR 2816/4885KDM4B 2531/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 ABL1 1411/4885BCR 2376/4885KDM4B 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback